Centrum für Diabetologie und Allgemeinmedizin
- Address
- Haus 4, Neue Mitte 10, Watzenborn-Steinberg, 35415 Pohlheim, Germany
Centrum für Diabetologie und Allgemeinmedizin
The Centrum für Diabetologie und Allgemeinmedizin is a specialized medical research facility dedicated to advancing the understanding and treatment of metabolic disorders, with particular emphasis on diabetes management and associated cardiovascular complications. The center focuses on investigating innovative therapeutic approaches for patients with complex metabolic profiles, including those with overlapping conditions of diabetes, obesity, and elevated cardiovascular risk.
- Type 2 diabetes mellitus treatment optimization and novel oral antidiabetic agents
- Cardiovascular risk reduction in metabolic disease populations
- Weight management strategies in diabetic and overweight patients
The center participates in cutting-edge clinical trials examining major adverse cardiovascular events (MACE) outcomes in patients with type 2 diabetes and concurrent weight disorders. Their research portfolio includes comparative effectiveness studies evaluating novel oral antihyperglycemic medications against established treatments like insulin glargine, contributing valuable evidence to guide clinical practice in managing patients with metabolic syndrome and elevated cardiovascular risk profiles.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novo Nordisk A/S2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centrum für Diabetologie und Allgemeinmedizin
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | Jun 2026 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 2 | Unknown | 2023-08-02 | 2023-08-02 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.